UPDATE: Morgan Stanley Downgrades Teva Pharmaceuticals to Equal-Weight - Teva Pharmaceutical Indus (NYSE:TEVA)

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.

Morgan Stanley lowers its rating on Teva Pharmaceuticals (NASDAQ: TEVA) to Equal-weight from Overweight while reiterating the price target of $47 a shre, as it believes the company's risk to reward ratio is now more balanced. Morgan Stanley says, "An improved outlook, $3B share buyback, and new CEO Jeremy Levin have driven Teva's multiple from 7x to ~8x, but we now see the risk-reward as balanced in the context of our relative rating system. ...We and consensus expect Teva to prevail on Copaxone patent litigation. We see $1–$2 stock upside if Teva wins and $5–$6 downside if Teva surprisingly loses."TEVA closed at $45.71 a share on Friday.

27% profit every 20 days?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!